Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$1.30 -0.4%	$1.28	$0.85 ▼ $4.40	$41.67M	0.29	31,725 shs	4,602 shs
AVTX Avalo Therapeutics	$3.87 +4.0%	$5.07	$3.39 ▼ $16.00	$41.90M	0.87	54,119 shs	26,971 shs
KPTI Karyopharm Therapeutics	$4.28 -5.6%	$5.06	$3.51 ▼ $17.40	$36.95M	0.33	81,844 shs	70,113 shs
TLPH Talphera	$0.49 0.0%	$0.52	$0.45 ▼ $1.19	$10.05M	-0.15	71,984 shs	17,068 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	-0.38%	+1.57%	-5.47%	+48.85%	-27.65%
AVTX Avalo Therapeutics	+3.62%	-4.86%	-25.60%	-49.11%	-69.13%
KPTI Karyopharm Therapeutics	+1.12%	-2.37%	-28.66%	-43.02%	-68.62%
TLPH Talphera	-0.69%	-2.98%	+0.62%	-12.60%	-52.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	2.824 of 5 stars	3.4	3.0	0.0	0.0	2.5	1.7	1.3
KPTI Karyopharm Therapeutics	4.0096 of 5 stars	3.5	0.0	0.0	4.6	3.6	2.5	0.6
TLPH Talphera	2.1623 of 5 stars	3.8	2.0	0.0	0.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	0.00	N/A	N/A	N/A
AVTX Avalo Therapeutics	2.83	Moderate Buy	$33.00	752.71% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	910.53% Upside
TLPH Talphera	3.50	Strong Buy	$5.00	920.41% Upside

Current Analyst Ratings Breakdown

Latest TLPH, AKTX, AVTX, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
4/1/2025	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00
3/25/2025	AVTX Avalo Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
3/20/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	AVTX Avalo Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$18.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00
2/28/2025	AVTX Avalo Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$48.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A
AVTX Avalo Therapeutics	$441K	95.02	N/A	N/A	$9.11 per share	0.42
KPTI Karyopharm Therapeutics	$142.13M	0.26	N/A	N/A	($1.47) per share	-2.91
TLPH Talphera	$27K	372.09	N/A	N/A	$0.83 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$10.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/18/2025 (Estimated)
AVTX Avalo Therapeutics	-$31.54M	N/A	0.00	N/A	N/A	N/A	-442.16%	122.99%	8/11/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)
TLPH Talphera	-$18.40M	-$0.45	N/A	N/A	N/A	N/A	-118.46%	-65.82%	8/12/2025 (Estimated)

Latest TLPH, AKTX, AVTX, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/31/2025	Q4 2024	TLPH Talphera	-$0.21	-$0.07	+$0.14	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.29	0.29
AVTX Avalo Therapeutics	N/A	1.42	1.42
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
TLPH Talphera	N/A	4.42	4.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
AVTX Avalo Therapeutics	87.06%
KPTI Karyopharm Therapeutics	66.44%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.90%
AVTX Avalo Therapeutics	3.03%
KPTI Karyopharm Therapeutics	2.75%
TLPH Talphera	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	16.25 million	Not Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.37 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable
TLPH Talphera	19	20.50 million	16.48 million	Optionable

TLPH, AKTX, AVTX, and KPTI Headlines

Recent News About These Companies

Talphera (NASDAQ:TLPH) Stock Price Up 0.4% - Here's Why

May 24, 2025 | americanbankingnews.com

Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 17, 2025 | finanznachrichten.de

Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025

May 16, 2025 | uk.investing.com

Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing

May 15, 2025 | msn.com

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | prnewswire.com

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025 | prnewswire.com

All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy

May 7, 2025 | msn.com

Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?

April 5, 2025 | msn.com

Talphera reports Q4 EPS (7c) vs. (25c) last year

April 1, 2025 | markets.businessinsider.com

Talphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Talphera announces agreement with FDA to reduce NEPHRO CRRT study size

April 1, 2025 | markets.businessinsider.com

Talphera Reports 2024 Financial Results and Study Update

March 31, 2025 | tipranks.com

Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad

March 31, 2025 | msn.com

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | prnewswire.com

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

March 31, 2025 | prnewswire.com

7TLPH : Earnings Outlook For Talphera

March 28, 2025 | benzinga.com

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

March 26, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH, AKTX, AVTX, and KPTI Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$1.30 -0.01 (-0.38%)

As of 01:03 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Avalo Therapeutics NASDAQ:AVTX

$3.87 +0.15 (+4.03%)

As of 01:29 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Karyopharm Therapeutics NASDAQ:KPTI

$4.28 -0.26 (-5.63%)

As of 01:29 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Talphera NASDAQ:TLPH

$0.49 0.00 (-0.02%)

As of 01:29 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time